Chandler Chicco Companies Tops PR Week's Healthcare League Tables


LONDON, July 1, 2008 (PRIME NEWSWIRE) -- Chandler Chicco Companies (CCC), a part of inVentiv Health (Nasdaq:VTIV), has reason to celebrate this week after it was named the UK's leading healthcare consultancy.

The league tables are produced by the industry's own publication, PR Week and are ranked by the audited healthcare specific fees the agency generated in the previous year. Last year CCC held the number two slot but as a result of staggering growth of 47% in 2007 leap-frogged into the lead position.

CCC attributes its growth to a combination of new clients, growth from existing accounts and diversification of services it provides. CCC now works on a total of 70 brands from its London office.

Last year also saw the agency acquired by U.S. pharmaceutical marketing company inVentiv Health Inc., helping extend international partnerships outside traditional brand PR, such as the World Diabetes Foundation campaign.

While the agency has a host of ethical clients, it is also expanding its consumer health division and the appointment by Danone in 2007 was a big win for the team.

Commenting on the agency's success, EU director of operations, Fiona Hall says: "We are delighted to be named the UK's leading healthcare agency which is a testament to the hard work and drive that the CCC team offers to our business. 2008 already looks set to be another successful year so we are aiming to maintain our number one spot!"

About Chandler Chicco Companies

At Chandler Chicco Companies, we're engaged by the challenge, inspired by the possibilities and dedicated to always doing work that's a step ahead of others in healthcare communications. We are empowered with the freedom to examine and interpret the world around us, and the power to make a difference in people's lives. There are six organizations in all that make up Chandler Chicco Companies: Chandler Chicco Agency, Biosector 2, 'nition, Litmus, Determinus and Brandtectonics.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq:VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.

The inVentiv Health, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4942

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.



            

Contact Data